Fulgent Genetics, Inc.
FLGT
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $560.3M
$19.73
▲ +0.41%
P/E
-7.00
Mkt Cap
$560.3M
52-Wk Range
$13.46–$31.04
52-Week Range
$13.46 - $31.04
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 11.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary next-generation sequencing (NGS) platform enabling rapid, cost-effective testing at scale
- Comprehensive test menu spanning oncology, carrier screening, infectious disease, and rare genetic disorders
- Established relationships with major payors, hospitals, and medical institutions ensuring steady revenue streams
- Vertical integration of laboratory operations reducing costs and improving turnaround times
- Strategic partnerships with Helio Health and other entities expanding addressable market in early cancer detection
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Steady revenue growth (14% YoY)
Value
Deep value opportunity - significant discount to Life Sciences Tools peers
Momentum
Strong
+7.8% over 3m
Quality
Stable
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying FLGT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 6, 2026
JUL 30, 2026
Reported EPS of -$0.58 vs -$0.46 consensus (-26.1% surprise). Revenue of $85.4M vs $94.0M expected (-9.2%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-26.1%
Revenue trend · last 8Q
—
+8%
+14%
+15%
+17%
+9%
-3%
+4%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$71.7M
$76.2M
$73.5M
$81.8M
$84.1M
$83.3M
$71.1M
$85.4M
Margins · last 8Q
Gross
30.1%
Operating
-34.8%
Profit
-34.6%
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · Aug 4, 2026
vs Industry
How FLGT stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related